Cargando…

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC

SIMPLE SUMMARY: Immunotherapy with immune checkpoint inhibitors has recently brought a paradigm shift in the treatment of non-small cell lung cancer (NSCLC), but until now, most clinical benefits of immunotherapy have been demonstrated in the setting of advanced or metastatic disease. However, there...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roller, John F., Veeramachaneni, Nirmal K., Zhang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833612/ https://www.ncbi.nlm.nih.gov/pubmed/35159008 http://dx.doi.org/10.3390/cancers14030741

Ejemplares similares

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
por: Lee, Jay M., et al.
Publicado: (2021)

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)

Targeting interleukin-1β and inflammation in lung cancer
por: Zhang, Jun, et al.
Publicado: (2022)

Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
por: Domvri, Kalliopi, et al.
Publicado: (2013)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
por: Lv, Lulu, et al.
Publicado: (2022)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy
por: Ghio, Michael, et al.
Publicado: (2023)

Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
por: Kang, Sandra, et al.
Publicado: (2022)

Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
por: Longoria, Teresa C., et al.
Publicado: (2015)

The evolving landscape of immunotherapy for the treatment of allergic conditions
por: Pandya, Aarti, et al.
Publicado: (2023)

New modalities of cancer treatment for NSCLC: focus on immunotherapy
por: Davies, Marianne
Publicado: (2014)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
por: Yan, Dan
Publicado: (2023)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
por: Kanani, A, et al.
Publicado: (2021)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Evolving role of immunotherapy in the treatment of refractory warts
por: Thappa, Devinder M, et al.
Publicado: (2016)

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
por: Wang, Xianwang, et al.
Publicado: (2023)

NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know
por: Mitchell, Carley L., et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Lung Cancer Surgery after Neoadjuvant Immunotherapy
por: Stefani, Dirk, et al.
Publicado: (2021)

Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
por: Oitabén, Ana, et al.
Publicado: (2022)

Neoadjuvant immunotherapy followed by surgery with curative intent in 35 patients with advanced NSCLC: the retrospective experiences of a multidisciplinary team
por: Ma, Dongjie, et al.
Publicado: (2022)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy
por: Brar, Gagandeep, et al.
Publicado: (2018)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC
por: Stafford, Margaret, et al.
Publicado: (2020)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
por: Dietrich, Brian, et al.
Publicado: (2018)

The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review
por: Hamoud, Bashar Haj, et al.
Publicado: (2023)

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
por: Zarogoulidis, Paul, et al.
Publicado: (2022)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1uae3v2qohdg5v541iplpual6l